 |
|
Immunohistochemical Expression of Platelet Growth Factor and Vascular Endothelial Growth Factor in Patients With Melanoma With and Without Redness (Brenner Sign)
Jacob Mashiah, MD;
Yonit Wohl, MD;
Yoav Barnea, MD;
Shlomo Schneebaum, MD;
Andrea Gat, MD;
Faina Misonzhnik-Bedny, BSc;
Sarah Brenner, MD
Arch Dermatol. 2007;143(8):1001-1004.
Objective To assess whether an erythematous eruption in the vicinity of or distant from a melanoma lesion might be related to the vascular endothelial growth factor, the platelet-derived endothelial cell growth factor, or both.
Methods Biopsy specimens from 13 patients with primary melanoma, 6 of whom had erythematous eruptions and 7 who did not, were studied by immunohistochemistry for the expression of vascular endothelial growth factor and platelet-derived endothelial cell growth factor.
Results Vascular endothelial growth factor was positive in 3 of 6 patients (50%) with melanoma and redness (Brenner sign) and in 4 of 7 patients (57%) with melanoma without redness. Platelet-derived endothelial cell growth factor was positive in all 6 patients (100%) with melanoma and redness and in 4 of 7 patients (57%) with melanoma without redness.
Conclusion Platelet-derived endothelial cell growth factor may have a part in the pathogenesis of the redness observed in patients with melanoma, called Brenner sign, by affecting vasculature function.
Author Affiliations: Departments of Dermatology (Drs Mashiah, Wohl, and Brenner), Plastic Surgery (Dr Barnea), General Surgery A (Dr Schneebaum), and Pathology (Dr Gat and Ms Misonzhnik-Bedny), Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Differences in Cytokine Levels in Melanoma Patients with and without Redness (Brenner Sign)
MASHIAH et al.
Anticancer Res 2009;29:1793-1796.
ABSTRACT
| FULL TEXT
|
